Source: Annual Congress 2005 - Asthma management III
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Pedersen, P. M. O‘Byrne, W. W. Busse, W. C. Tan, Y. Z. Chen, B. Lindberg, F. Radner, C. J. Lamm (Kolding, Denmark; Hamilton, Canada; Madison, United States Of America; Singapore, Singapore; Beijing, China; Lund, Sweden). Fracture rate in patients with asthma receiving long-term early intervention with budesonide: the START study. Eur Respir J 2005; 26: Suppl. 49, 1855

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of early intervention with budesonide in mild persistent asthma — 5-year data from the START study Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 Early intervention with budesonide in mild persistent asthma - the START study. On behalf of the START investigators group Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Country-specific cost-effectiveness of early intervention with budesonide in mild asthma Source: Eur Respir J 2004; 24 : 568-574 Year: 2004 Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study Source: ERJ Open Res, 6 (1) 00246-2019; 10.1183/23120541.00246-2019 Year: 2020 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 The cost-effectiveness of early intervention with inhaled budesonide once daily: an international comparison of the results from the START study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study Source: Eur Respir J, 57 (2) 2000515; 10.1183/13993003.00515-2020 Year: 2021 Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Long-term safety data with once-daily budesonide in mild asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 Three-year prospective cohort study of growth in asthmatic children prescribed appropriate inhaled corticosteroid (ICS) doses Source: Eur Respir J 2004; 24: Suppl. 48, 614s Year: 2004 The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003